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Background: Upper tract urothelial carcinoma (UTUC) is a tumor with sizable metastases and local recurrence. It
has a worse prognosis than bladder cancer. This study was designed to investigate the urinary potential tumor
markers of UTUC.
Methods: Between January 2008 and January 2009, urine was sampled from 13 patients with UTUC and 20 healthy
adults. The current study identified biomarkers for UTUC using non-fixed volume stepwise weak anion exchange
chromatography for fractionation of urine protein prior to two-dimensional gel electrophoresis.
Results: Fifty five differential proteins have been determined by comparing with the 2-DE maps of the urine of
UTUC patients and those of healthy people. Western blotting analysis and immunohistochemistry of tumor tissues
and normal tissues from patients with UTUC were carried out to further verify five possible UTUC biomarkers,
including zinc-alpha-2-glycoprotein, calreticulin, annexin A2, annexin A3 and haptoglobin. The data of western blot
and immunohistochemical analysis are consistent with the 2-DE data. Combined the experimental data in the urine
and in tumor tissues collected from patients with UTUC, the crucial over-expressed proteins are calreticulin, annexin
A2, and annexin A3.
Conclusions: Calreticulin, annexin A2, and annexin A3 are very likely a panel of biomarkers with potential value for
UTUC diagnosis.
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Urothelial (transitional cell) carcinoma is the most com-
mon malignancy in epithelium of the bladder, ureter,
and kidney. Upper tract urothelial carcinoma (UTUC) is
relative rare and accounting for 5% of all urothelial neo-
plasms. Three quarters of the UTUC incidence occur
in renal pelvis. The overall incidence rate of UTUC in
Taiwan is higher than that in worldwide else [1]. Investi-
gation suggested this is due to a wide usage of herb drug* Correspondence: wyr924@ms24.hinet.net
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unless otherwise stated.such as Aristolochia manshuriensis Kom and analgesics
in Taiwan. Bladder cancer rarely migrates to upper tract.
Patients with UTUC have a higher risk of developing
bladder cancers (30-50%) [2]. In contrast to the applica-
tion of transurethral resection and intravesical chemo-
therapy to avoid cystectomy in life time for early stage
bladder cancer, UTUC mostly undergo radical nephrour-
eterectomy with the risk of hemodialysis. Oftentimes
UTUC has a poorer prognosis than bladder cancer [3,4].
Reports regarding medically useful tumor markers for
UTUC are very limited. The common manifestations of
urothelial carcinomas are gross hematuria. Most of the
urological diseases, such as urinary tract infection, benignThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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hematuria. The available diagnostic methods for UTUC
are urine cytology, CT urography, and cystoscopy. How-
ever, the sensitivity and specificity of these manners are
not satisfactory.
Proteomic analysis of tissues or body fluids has been
applied in clinical detections. Identification of disease
biomarkers is potentially useful for diagnosis, monitoring
disease progress as well as evaluation of therapies. Two-
dimensional gel electrophoresis (2-DE) is an essential
tool for proteome studies. It has been used in biomarker
identification for diagnosis and clinical monitoring of dis-
eases [5]. Urine contain large amount of high-abundance
proteins such as immunoglobulin heavy and light chain
proteins, generally obscure low-abundance proteins on 2-
DE maps. Previously a non-fixed volume stepwise isocratic
elution weak anion exchange (WAX) chromatography was
used to fractionate healthy urine proteins into four groups
prior to performing two dimensional electrophoresis and
the results indicated that low-abundance proteins can be
detected on 2-DE maps and identified by LC-MS/MS ana-
lysis after the removal of high-abundance proteins [6].
Herein our study identifies biomarkers for UTUC using
non-fixed volume stepwise WAX chromatography for
fractionation of urine protein prior to 2-DE and using
comparative proteomic analysis for the detection of differ-
ential proteins. The urine proteins of patients with UTUC
were fractionated into four fractions following the same
procedures for that of healthy people. Differential protein
spots were detected by comparing the 2-DE maps of
UTUC patients with those of healthy people. The differen-
tial protein spots were identified and further evaluated by
urine western blotting analysis while tumor tissues col-
lected from UTUC patients were further assessed by
immnohistochemistry and western blot to provide poten-
tially important protein markers for UTUC.
Methods
This protocol was approved by the Institute Review
Board of the Buddhist Dalin Tzu Chi Hospital (Approval
No. B09601020). We obtained all patients’ consent for
both the urine collection and the tumor sample collec-
tion and use.
Collection of urine of healthy people
Urine samples were collected from 20 healthy individ-
uals including eleven males and nine females, aged be-
tween 18 and 54 years, who had neither history of drug
administration nor renal disorders during sample collec-
tion period. All females had no menstruation at the time
of sample collection. A 100 ml urine sample was collec-
ted for every person in the mornings and the samples
were combined together. The urine samples were treated
with protease inhibitor cocktail to avoid proteolysis.They were then centrifuged at 12,000 rpm to remove in-
soluble material and cell debris at 4°C. Stirred Ultrafil-
tration Cell 8400 (Millipore, Billerica, MA, USA) and
YM5 membrane (5000 molecular weight cut-off ) were
used to concentrate the solution and remove small inter-
ference molecules. The concentrated urine samples had
a final volume of 50 ml and were stored at −80°C for fu-
ture use.
Collection of urine of patients with UTUC
The incidence of UTUC is relatively rare and it is diffi-
cult to have a large number of patients in a local area. A
total of 13 patients with UTUC enrolled in this study be-
tween January, 2008 and January, 2009. There were 5
male and 8 female. The average age was 62.6 years (33–
80 years old). All the patients were newly diagnosed and
confirmed by histological examination. A 100 ml urine
sample was collected for each patient prior to surgery
and the samples were combined together. The further
treatments of the samples adopted the same procedures
for the samples of healthy people.
Collection of tumor tissue of patient with UTUC
The tissue specimen were harvested by nephroureterect-
omy for UTUC. In addition, the normal control epithe-
lium was resected from approximately 1 cm away from
the tumor. The tissue was collected at least 5 mm ×
5 mm × 5 mm in size. These tissues were immediately
stored in liquid nitrogen for later analysis.
Fractionation of urine proteome by non-fixed volume
stepwise WAX
According to the previous procedures [6], a column
(5 cm × 10 cm) packed with 50 gram DEAE-Sephacel
(GE Healthcare) which was equilibrated with 50 mM
Tris–HCl buffer for five times before use. Twenty ml of
concentrated urine samples were dialyzed at 4°C over-
night and then loaded to the column. First the column
was eluted by 50 mM Tris–HCl buffer without salt at a
flow rate of 40 ml/hr. The column was eluted until no
proteins were detected in the eluent by Bradford dye
assay. A total combined eluent was collected and con-
centrated by Stirred Ultrafiltration Cell 8400 and YM5
membrane to a volume of 50 ml. The sample was called
fraction unbound. Then, a solution of 50 mM NaCl/
50 mM Tris–HCl buffer was used to elute the column
until no protein was detected in the eluent and a total
solution was collected and concentrated by the same
procedure to obtain the fraction NaCl-1. 100 mM NaCl/
50 mM Tris–HCl buffer was collected following the
same procedures to obtain fraction NaCl-2. 1 M NaCl/
50 mM Tris–HCl buffer was collected for the last elu-
tion to obtain fraction NaCl-3.
Lu et al. BMC Cancer 2014, 14:363 Page 3 of 13
http://www.biomedcentral.com/1471-2407/14/363Urine proteins precipitation and two-dimensional gel
electrophoresis
The urine protein mixture in the supernatant was pre-
cipitated out overnight at −20°C by 100 ml 10% TCA/
Acetone solution containing 20 mM DTT [7]. The pellet
was rinsed in cold acetone containing 20 mM DTT and
dried by SpeedVac, then resuspended in a rehydration
buffer (8 M urea, 0.5% CHAPS, 0.5% IPG buffer, 20 mM
DTT, 0.002% bromophenol blue) at 4°C overnight. The
protein contents were determined using 2-D Quant Kit
(GE Healthcare).
The first dimension electrophoresis (isoelectric focus-
ing) was performed GE Healthcare Ettan IPGphor 3
using the reported procedure [8]. Urine proteins (50 μg)
were loaded on 11-cm strip. Every 11-cm IPG strip (pI
4–7 and pI 3-10NL, Immobiline DryStrip) was rehy-
drated at 50 V for 12 h, then focused according to the
preset program: 200 V (2 h), 500 V (1 h), 1,000 V (1 h),
4,000 V (2 h), 8,000 V (3 h), until the total Vh reached
32,060. Then second dimension electrophoresis was
done 15% SDS-PAGE run at 150 V for 7 h. The second
dimension electrophoresis was used SE 600 Ruby elec-
trophoretic unit (Hoeffer). The 2-DE gels were stained
with silver staining and then subjected to image analysis
with the PDQuest 2-D software (version 7.1.1). 2-DE im-
ages were taken in triplicate for each sample and nor-
malized prior to statistical analysis.
Protein spot identification by LC-MS/MS
The protein spots of interest were excised, destained and
then subjected to tryptic in-gel digestion as described in
a previous report [9].
The peptide solution was concentrated for the follow-
ing LC-MS/MS analysis. After desalting with a Millipore
ZIP plate (Millipore), the above peptide mixture was
separated by nanoflow reversed phase C18 chromatog-
raphy on nano LC using the Agilent NanoLC 1200 Sys-
tem and Agilent Zobax 2.1 mm × 150 mm C18 column.
MS analysis was performed using a AB SCIEX QTRAP®
5500Q mass spectrometer (Applied Biosystems, CA,
USA). The scan range was from m/z 100 to 1000 for
MS. The raw data was processed into a text file format
of WIFF with Analyst 1.5.1. MASCOT was used in
searching for protein identification by NCBInr protein
database.
Western blot analysis
Western blot was conducted to verify the regulation of 5
differential 2-DE-detected proteins. The protein samples
under reducing conditions were loading 20 μg total pro-
teins and separated by 12.5% SDS-PAGE. The proteins
on the gel were then transferred to PVDF membranes.
The membranes were incubated with rabbit antibodies
against human calreticulin (CALR), annexin A2, annexinA3, haptoglobin (Hp), and zn-alpha-2-glycoprotein (ZAG)
at 4°C for 2 h or overnight. The membranes were washed
three times in PBST (10 mM NaH2PO4, 130 mM NaCl,
0.05% Tween 20), then incubated with the second anti-
bodies (goat anti-rabbit with horseradish peroxidase
conjugated, 1:5,000 in blocking solution) for 1 h. After
washing with PBST for three times, the blots were visual-
ized through chemiluminesence by adding ECL western
blotting reagents.
Immunohistochemistry
Using the Bond-Max autostainer (Leica Microsystems),
slides were stained with annexin A2 polyclonal anti-
bodies (1:50; ProteinTech Group, Chicago, IL, USA) ap-
plied at room temperature for 1 h. Briefly, formalin-fixed
and paraffin-embedded tissue array specimens were in
Tris–HCl buffer (50 mM Tris, 130 mM NaCl, 0.05%
Tween 20), rehydrated through serial dilutions of alco-
hol, and washed in PBST. Slides were stained with previ-
ously mentioned antibodies was performed on the fully
automated Bond-Max system using onboard heat in-
duced antigen retrieval and a Leica Refine polymer de-
tection system (Leica Microsystems). Diaminobenzidine
was used as the chromogen (Leica Microsystems) in all
these immunostainings. Negative controls were obtained
by excluding the primary antibody. Appropriate positive
controls were used throughout the study. These slides
were mounted with gum for examination and the images
were captured by the Olympus BX51 microscopic/DP71
Digital Camera System (Ina-shi, Nagano, Japan) for stu-
dy comparison.
Results
The characteristics of UTUC patients and controls
There were eight males and five females in the UTUC
group while eleven males and nine females are in the
healthy control group. The mean ages of UTUC patients
and healthy controls were 62.6 years (range 33–80 years)
and 34.2 years (range 18–54 years), respectively. In the
UTUC group, there were 8 (61.5%) patients with stage
pT1/T2, 5 (38.5%) with stage pT3. Among these UTUC
patients, 23.1% (3/13) had grade 3 tumors. Most of the
patients had solitary tumors (69.3%) and big lesions
(76.9% with >4 cm in diameter). However, only 66.7%
(6/9) patients showed carcinoma cell in urine cytology
(Table 1).
2-DE maps of urine proteome of healthy people and
UTUC patients
A 100 ml urine sample was collected from each of 20
healthy people and 13 UTUC patients. In order to elim-
inate the individual difference, the samples were com-
bined together. The proteins were precipitated by 10%
TCA/Acetone after dialysis. An equal amount of 50 g
Table 1 The characteristics of UTUC patients and controls
UTUC Control
N = 13 N = 20
Sex
Male 8 (61.5%) 11 (55.0%)
Female 5 (38.5%) 9 (45.0%)
Mean age (years) 62.6 (33–80) 34.2 (18–54)
Tumor grade
G1 7 (53.8%) -
G2 3 (23.1%) -
G3 3 (23.1%)
T Stage
T1 4 (30.7%) -
T2 4 (30.7%) -
T3 5 (38.5%) -
Urine cytology
Positive 6 (46.2%) -
Negative 3 (23.1%) -
Unknown 4 (30.7%) -
Tumor size
<1 cm 0 (0%) -
1-4 cm 3 (23.1%) -
>4 cm 10 (76.9%) -
Tumor multiplicity
Solitary 9 (69.3%) -
Multiple 4 (30.7%) -
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pI 3-10NL). The protein spots were visualized with silver
stain. The differential proteins in the urine proteome of
UTUC patients were examined by comparing with those
of healthy people (Figure 1).Volume stepwise WAX with NaCl solutions
A direct 2-DE analysis of a complex protein sample
would encounter resolution problem. Usually not all pro-
teins can be identified on a 2-DE map. In order to identify
the differential proteins in the urine proteome of patients
with UTUC in comparison with that of healthy people,
the urine proteome of patients with UTUC was also frac-
tionated into four fractions using the same experimental
procedures and conditions. The 2-DE maps of the four
fractions of patient with UTUC were shown in Figure 2
(2A for the fraction Unbound, 2B for the fraction NaCl-1,
2C for the fraction NaCl-2, and 2-DE for the fraction
NaCl-3; 2A-2D for UTUC patient, 2E-2H for healthy
people). The Figure 3A-3F showed the corresponding
2-DE maps of the four fractions of urine proteome ofUTUC patients and healthy people run on pI 3–10 NL.
(3A-3D for UTUC patient, 3E-3H for healthy people)
A side-by-side comparison between the 2-DE maps of
each fraction of patients and those of healthy people
showed clearly different staining patterns. A total of 208
protein spots were detected in Figure 2A comparing
with 53 protein spots in Figure 2E, a total of 369 spots
were detected in Figure 2B comparing with 102 protein
spots in Figure 2F, a total of 350 spots were detected
in Figure 2C comparing with 143 protein spots for
Figure 2G, and a total of 101 spots were detected in
Figure 2D comparing with 31 protein spots in Figure 2H
by comparative analysis using PDQuest 2-D software
(version 7.1.1). A total of 1028 protein spots were shown
in Figure 2A-2D comparing with a total of 329 protein
spots in Figure 2E-2H.
Analysis of all the differential protein spots would en-
counter practical difficulties. Identification of fifty-five
(spot 1 ~ 55) differential protein spots by LC-MS/MS
after excision and in-gel digestion was carried out and
the identities are represented in Table 2. The differential
proteins spots were defined as the proteins only present
in patients or showed intensity difference between pa-
tients and healthy people using PDQuest 2-D software.
The differential proteins include zinc-alpha-2-glycopro-
tein (ZAG), heparan sulfate proteoglycan (HSPG), alpha-
1-microglobulin/bikunin precursor, calreticulin (CALR),
haptoglobin (Hp), serotransferrin, ATP-binding cassette
sub-family A member 9, annexin A2, annexin A3 sorting
nexin-14, Serum albumin, spermatogenesis-associated
protein 7, DNA replication licensing factor MCM2,
proline-serine-threonine phosphatase-interacting protein
1, dermcidin precursor, glial fibrillary acidic protein,
syntaxin-binding protein 4, and transthyretin.
Western blot analysis of urine and tissue
Western blot analysis of specific urine proteins was per-
formed to verify the 2-DE results. Western blot data of
ZAG, CALR, annexin A2, annexin A3 and Hp in the
urine of both patients and healthy people are shown in
Figure 4. The results indicated that clearly stronger ex-
pression of ZAG, CALR, annexin A2, annexin A3 and
Hp in the urine of patients in comparison with the
counterparts in the urine of healthy people. This con-
firmed the 2-DE data of ZAG (spots 23,24), CALR (spot
31), annexin A2 (spot 53), annexin A3 (spot 29) and Hp
(spot 32 ~ 36). Side-by-side comparisons of CALR, ZAG,
annexin A2, annexin A3 and Hp showed the different
expression between tumor tissues and normal tissues.
The expression of CALR, annexin A2, and annexin A3
in the tumor tissues was higher than that in the normal
tissues. These results are in accordance with the western
blot data on the urine samples of UTUC patients as
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Figure 1 Two-DE maps of urine proteome of UTUC and healthy people. (A)(C) 2-DE maps were for UTUC and (B)(D) for healthy people.
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tumor tissues (Figure 5).
Immunoreactivity of annexin A2
The immunoreactive staining detected by annexin A2
antibodies appeared in layers of UTUC tissue and nor-
mal tissue confined to the two proteins in the cytoplasm
of the epithelium. The immunoreactive expression of
the tumor tissue is stronger than that in normal tissues
(Figure 6). The positive staining rate of urothelial carcin-
oma was 84.6% (11/13), compared to control with 7.7%
(1/13). All 2 UTUCs with negative annexin A2 ex-
pression were pT1G1. The only normal urothelium with
postive expression was harvested from a patient with
pT3G3 (Table 3). The sensitivity and specificity of an-
nexin A2 expression were 50% (2/4) and 100% (0/4) for
pT1, 100% (4/4) and 100% (4/4) for pT2, and 100% (5/5)
and 80% (1/5) for pT3, 71.4% (5/7) and 100% (7/7) for
G1, 100% (3/3) and 100% (3/3) for G2, and 100% (3/3)
and 66.7% (2/3) for G3, respectively (Table 4). Anyway,
the study failed to calculate statistical significance due to
samll sample size.
Discussion
The differential proteins in UTUC patients and those in
healthy controls were compared using proteomic ana-
lysis in this study. The ages of UTUC patients and heal-
thy controls were 62.6 years (range 33–80 years) and34.2 years (range 18–54 years), respectively. UTUC usu-
ally occurs in older patients and elderly people appear
high occurrence of progressive diseases such as type
2 diabetes mellitus and osteoarthritis. Moreover, the
elderly in Taiwan often have habits of taking medicine,
Chinese herbal medicine and nutritional supplements.
Hence, it is clinically difficult to find healthy controls of
similar age. We consider that certain urine different pro-
teins are attributed to old age. Therefore we design an
additive study to compare the proteins of normal and
tumor tissues from patients with UTUC. The further
study tries to clarify that those different proteins are pro-
duced by urothelial tumors rather than normal tissues.
However, non-fixed volume stepwise WAX chroma-
tography is an effective method to fractionate urine pro-
tein. Many low-abundance proteins in the urine of
UTUC patients were enriched and identified. A total of
1028 differential protein spots have been detected in the
four fractions by comparative proteomic analysis. LC-
MS/MS analysis has determined fifty-five protein spots.
We expected some proteins expression were related to
age difference. Investigation of the proteins were associ-
ated with incidence of cancers, including ZAG, CALR,
annexin A2, annexin A3 and Hp [10-14]. Some of the
proteins have not been reported yet in UTUC. The
2-DE data were further confirmed by western blot ana-
lysis indicating the over-expression of CALR, anne-
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Figure 2 2-DE maps of fractions of urine proteome of UTUC patients and healthy people obtained by non-fixed volume stepwise
elution DEAE-Sephacel anion exchange chromatography. (pI 4–7) (A), (E) unbound Proteins in fraction (B), (F) Proteins in fraction NaCl-1
obtained by elution with 50 mM NaCl. (C), (G) Proteins in fraction NaCl-2 obtained by elution with 100 mM NaCl. (D), (F) Proteins in fraction
NaCl-3 obtained by elution with 1 M NaCl. Images A, B, C and D are for UTUC patients. Images E, F, G and H for healthy people.
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Figure 3 2-DE maps of fractions of urine proteome of UTUC patients and healthy people with obtained by non-fixed volume stepwise
elution DEAE-Sephacel anion exchange chromatography. (pI 3–10 NL) (A), (E) unbound Proteins in fraction (B), (F) Proteins in fraction NaCl-1
obtained by elution with 50 mM NaCl. (C), (G) Proteins in fraction NaCl-2 obtained by elution with 100 mM NaCl. (D), (F) Proteins in fraction
NaCl-3 obtained by elution with 1 M NaCl. Images A, B, C and D are for UTUC patients. Images E, F, G and H for healthy people.
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Table 2 Summary of differential protein spots of urine between patients with UTUC and healthy people identified by
LC-MS/MS










1 ATP-binding cassette sub-family A member 9 Q8IUA7 184.2/6.49 10 1 38
2 sorting nexin-14 Q9Y5W7 102.8/6.4 17 3 34
3 serum albumin precursor P02768 69.3/5.92 1 2 57
4 F-box/WD repeat protein 1A Q9Y297 68.8/8.3 29 3 33
5 spermatogenesis-associated protein 7 Q9P0W8 67.6/5.9 3 4 34
6 actin P62736 41.9/5.23 2 9 45
7 cytokeratin 1 P04264 65.9/8.16 3 3 40
8 DNA replication licensing factor MCM2 P49736 101.8/5.34 40 1 50
9 proline-serine-threonine phosphatase-interacting protein 1 O43586 47.5/5.53 6 4 40
10 X box-binding protein 1 P17861 28.6/9.71 18 3 35
11 immunoglobulin kappa chain C region P01834 11.6/5.58 16 49 151
12 immunoglobulin kappa chain V-I region AG P01593 11.9/5.67 4 31 176
13 hemopexin precursor P02790 51.6/6.55 4 7 86
14 prostaglandin-H2 D-isomerase precursor P41222 21.0/7.66 3 12 33
15 immunoglobulin kappa chain C region P01834 11.6/5.58 22 49 217
16 gelsolin precursor P06396 85.6/5.9 9 7 208
17 SH3-containing GRB2-like protein 3 Q99963 39.2/5.27 16 8 32
18 hemoglobin subunit beta P68871 15.9/6.75 9 32 214
19 inter-alpha-trypsin inhibitor heavy chain H4 Q14624 103.2/6.51 13 10 243
20 cytokeratin 10 P13645 59.4/5.13 2 4 38
21 basement membrane-specific heparan sulfate proteoglycan core protein precursor P98120 468.8/6.06 116 4 2114
22 retinol Binding Protein 4 P02753 22.9/5.76 45 35 233
23 Zn-alpha2-glycoprotein P25311 34.7/5.71 14 45 378
24 Zn-alpha2-glycoprotein P25311 34.7/5.71 5 16 98
25 fibrinogen gamma chain precursor P02679 51.4/5.37 19 24 201
26 fibrinogen gamma chain precursor P02679 51.4/5.37 5 11 38
27 serotransferrin precursor P02787 77.0/6.81 7 5 48
28 serotransferrin precursor P02787 77.0/6.81 18 13 88
29 annexin A3 P12429 36.3/5.63 3 4 37
30 dermcidin precursor P81605 11.2/6.08 2 16 48
31 calreticulin P27797 48.1/4.29 19 36 493
32 haptoglobin P00738 45.1/6.13 39 13 432
33 haptoglobin P00738 45.1/6.13 41 20 466
34 haptoglobin P00738 45.1/6.13 49 17 668
35 haptoglobin P00738 45.1/6.13 19 15 271
36 haptoglobin P00738 45.1/6.13 5 13 77
37 glial fibrillary acidic protein P14136 49.8/5.42 2 4 43
38 alpha-1-microglobulin/bikunin precursor P02760 38.9/5.95 41 14 698
39 alpha-1-microglobulin/bikunin precursor P02760 38.9/5.95 48 15 732
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Table 2 Summary of differential protein spots of urine between patients with UTUC and healthy people identified by
LC-MS/MS (Continued)










40 alpha-1-microglobulin/bikunin precursor P02760 38.9/5.95 45 23 667
41 syntaxin-binding protein 4 Q6ZWJ1 61.7/5.16 4 7 40
42 mRNA cap guanine-N7 methyltransferase O43148 54.8/6.3 11 3 52
43 transthyretin precursor P02766 15.8/5.52 13 48 217
44 transthyretin precursor P02766 15.8/5.52 8 40 142
45 alpha-1-microglobulin/bikunin precursor P02760 38.9/5.95 5 11 63
46 alpha-1-microglobulin/bikunin precursor P02760 38.9/5.95 13 11 198
47 transthyretin precursor P02766 15.8/5.52 4 14 46
48 serine/threonine-protein kinase MRCK beta Q9Y5S2 194.1/5.91 3 2 56
49 serum albumin precursor P02768 69.3/5.92 51 25 594
50 serotransferrin precursor P02787 77.0/6.81 42 21 441
51 serum albumin precursor P02768 69.3/5.92 92 26 1359
52 serum albumin precursor P02768 69.3/5.92 48 26 662
53 annexin A2 P07355 38.58/7.57 28 37 505
54 Ig gamma-1 chain C region P01857 36.0/8.46 20 26 190
55 Ig gamma-1 chain C region P01857 36.0/8.46 12 25 104
Lu et al. BMC Cancer 2014, 14:363 Page 9 of 13
http://www.biomedcentral.com/1471-2407/14/363patients with UTUC in comparison with those of healthy
people.
CALR, an endoplasmic reticulum (ER) chaperone,
plays the role as a stress protein. The over-expression of
CALR occurs in several malignancies, such as breast,
prostate, liver, bladder, and lung cancers [15-18]. It has
been reported that the expressions of CALR in both










Figure 4 Comparison of CBR staining of western blot analysis of zinc
Annexin A3 and hapatoglobin (Hp) in urine of healthy people and ur
Lane H1-H3 for individual urine of three healthy people and Lane U1-U5 fowere higher than in those of healthy people [19,20]. Ele-
vated CALR expression was showed by 2-DE, western
blot analysis, and immunohistochemistry in the urine and
tissues of patients with bladder cancer [19]. Enzyme-
linked immunosorbent assay was used for testing CALR
with a sensitivity of 67.9% and a specificity of 80% for the
detection of bladder cancer [20]. Our study for the first
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Figure 5 Side-by-side comparison using western blot analysis of zinc-alpha-2-glycoprotein (ZAG), Calreticulin (CALR), annexin A2,
annexin A3 and hapatoglobin (Hp) of tumor tissues and normal tissuess, each well with a loading of 20 μg protein. Tumor tissue was
presented by T and normal tissue was presented by N.
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also found in and the tumor tissues of patients with
UTUC in comparison with healthy controls. Further-
more, in the current study this ER chaperone protein
was over-expressed in the tumor areas of seven tumor/ad-
jacent normal tissue pairs (87.5%). These data suggested
that CALR is a protein secreted from UTUC tumor tis-
sues and it is potentially a marker for UTUC.
Annexin A2 is calcium-dependent phospholipid-
binding protein. It is involved in several biological pro-
cesses such as immune responses, anti-inflammatory
effects, Ca2+ transport, Ca2+-dependent exocytosis, and
phospholipase A2 regulation. It also plays roles in the
regulation of cellular growth and signal transduction
pathways. Annexin A2, a potential serum marker for he-
patocellular carcinoma may play an important role inAlamroN
C2G2Tp
Figure 6 Immunoreactivity staining of annexin A2 expression from pa
positive in stroma, negative in urothelium. (B) pT1G1, negative in urothelia
positive in urothelial carcinoma. Magnification: (A,B,C,D) × 100.liver cancer progression [21]. Down-regulation of an-
nexin A2 in hepatocellular carcinoma cells reduced the
secretion of MMP, migration ability, and invasive poten-
tial and also affected the cytoskeleton rearrangement of
tumor cells [22]. Annexin A2 protein may play an im-
portant role in carcinogenesis of oral squamous cell
carcinoma (OSCC). It may also serve as a potential bio-
marker for different pathological grade of this tumor
[23]. This study is the first report on the presence of
annexin A2 in the urines of patients with UTUC. The
expression of annexin A2 in the tumor tissue of a pa-
tient with UTUC was higher than in the normal tissue
of the same patient by western blotting analysis and im-
munohistochemistry and the over-expression was also
found in the tumor areas of eleven tumor/adjacent
normal tissue pairs (84.6%). These data in our studyB1G1Tp
D2G3Tp
tients, using immunohitochemistry (IHC). (A) normal urothelium,
l carcinoma. (C) pT2G2, positive in urothelial carcinoma (D) pT3G2,
Table 3 The results of immunohistochemistry of annexin
A2 expression in UTUC and normal tissues by patient
(+: positive expression, −: no negative expression)
ID T stage Tumor grade UTUC Control
1 T1 G1 - -
2 T2 G2 + -
3 T2 G1 + -
4 T1 G1 + -
5 T3 G3 + -
6 T2 G1 + -
7 T3 G3 + -
8 T2 G1 + -
9 T3 G3 + +
10 T3 G2 + -
11 T1 G1 - -
12 T1 G1 + -
13 T3 G2 + -
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for UTUC.
Annexin A3 belongs to a family of phospholipid and
calcium binding proteins. It has been implicated in cell
migration and differentiation, immunomodulation, bone
formation and mineralization [24]. Annexin A3 also play
roles in cancer dependent autoimmne regulation against
angiogenesis [25], exosomes/prosteasomes [26,27], and
calcium dependent processes. Recently studies indicated
annexin A3 is an inversely correlated marker for co-
lorectal cancer [28], ovarian cancer [29], and prostate
cancer [30]. It has been shown that annexin A3 in urine
with a highly specific noninvasive marker for prostate
cancer early detection [27,31]. Similar to annexin A2, we
for the first time showed that the over-expression of
annexin A3 in the urine and tumor tissues of patients
with UTUC in comparison with healthy controls while
annexin A3 was over-expressed in the tumor areas of
eight tumor/adjacent normal tissue pairs (61.5%). EvenTable 4 Summary of annexin A2 expression in UTUCs
and controls
Annexin A2 UTUC Control
Expression Positive Negative Positive Negative
T Stage
T1 (N = 4) 2 (50%) 2 (50%) 0 (0%) 4 (100%)
T2 (N = 4) 4 (100%) 0 (0%) 0 (0%) 4 (100%)
T3 (N = 5) 5 (100%) 0 (0%) 1 (20.0%) 4 (80.0%)
Grading
1 (N = 7) 5 (71.4%) 2 (28.6%) 0 (0%) 7 (100%)
2 (N = 3) 3 (100%) 0 (0%) 0 (0%) 3 (100%)
3 (N = 3) 3 (100%) 0 (0%) 1 (33.3%) 2 (66.7%)though two UTUC tumor tissues and most normal tis-
sues did not express annexin A3, both annexin A2 and
annexin A3 showed stronger expression in UTUC urine
samples than those in the urine of healthy control. This
demonstrates that high-level expression of annexin A2/
A3 in human urine samples still highlights their biomed-
ical and diagnostic value for UTUC.
ZAG is a special protein. It stimulates lipid degener-
ation in adipocytes [32] and appears over-expressed in
certain tumors and has been often recognized as a pos-
sible cancer marker [33-35]. It has been reported that
ZAG initially appeared in urinary tract luminal surface.
During the progression of the tumor, it transformed to
the basal location. The highest level of ZAG among in-
vasive bladder cancer sites was at the stage pT2-3 [33].
Hp promotes the accumulation of hydroxyl radicals
which causes oxidative tissue damages [36]. Hp exists in
two allelic forms in human body, denoted as Hp1 and
Hp2. Elevated expression of Hp2 was reported in the
plasma of patients with pancreatic, cervical, and breast
cancer [36-38]. The results of this study demonstrated
that ZAG and Hp had a stronger intensity in the urines
of UTUC patients than in those of healthy people. How-
ever, higher expression of ZAG and Hp was not found
in the western blot data of tumor tissues. We propose
that the over-expression of ZAG and Hp in the urine of
UTUC patients compared with that in healthy people,
even though not consistent with the data in tumor tis-
sues, it still somewhat reflects the possibilities of dis-
eases or tumors in the urinary tract.
Conclusions
Comparative proteomic analysis was conducted to inves-
tigate potential tumor markers for UTUC. A non-fixed
volume stepwise elution anion exchange chromatog-
raphy using DEAE-Sephacel as gel resin was employed
to fractionate the total urine into four fractions prior to
performing 2-DE. The 2-DE map of the urine of patients
with UTUC showed a total of 1,028 proteins spots.
Among them, fifty-five differential spots were identified.
Three proteins, CALR, annexin A2 and annexin A3 pre-
sented with over-expression in both the urine and tis-
sues of UTUC patients in comparison with that in the
healthy and normal counterparts. The data on the urine
and tumor tissues obtained from UTUC patients which
were discovered and verified by proteomic and immuno-
logical analysis strongly suggested that CALR, annexin
A2 and annexin A3 are essential proteins secreted from
UTUC tumor tissues. Our study also established the bio-
medical linkage of the critical over-expression of CALR,
annexin A2 and annexin A3 between the urine and
tumor tissues of UTUC patients. CALR, annexin A2 and
annexin A3 are very likely a panel of crucial markers in
UTUC patients.
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